Bortezomib
Jump to navigation
Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
Bortezomib is a proteasome inhibitor to treat multiple myeloma and mantle cell lymphoma. The substance prevents degradation of pro-apoptotic factors, resulting activation of programmed cell death in neoplastic cells. [1]
References
- ↑ Curran, MP.; McKeage, K. (2009). "Bortezomib: a review of its use in patients with multiple myeloma.". Drugs 69 (7): 859-88. doi:10.2165/00003495-200969070-00006. PMID 19441872.